496 related articles for article (PubMed ID: 27856208)
1. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.
Hare JM; DiFede DL; Rieger AC; Florea V; Landin AM; El-Khorazaty J; Khan A; Mushtaq M; Lowery MH; Byrnes JJ; Hendel RC; Cohen MG; Alfonso CE; Valasaki K; Pujol MV; Golpanian S; Ghersin E; Fishman JE; Pattany P; Gomes SA; Delgado C; Miki R; Abuzeid F; Vidro-Casiano M; Premer C; Medina A; Porras V; Hatzistergos KE; Anderson E; Mendizabal A; Mitrani R; Heldman AW
J Am Coll Cardiol; 2017 Feb; 69(5):526-537. PubMed ID: 27856208
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): a phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy.
Mushtaq M; DiFede DL; Golpanian S; Khan A; Gomes SA; Mendizabal A; Heldman AW; Hare JM
J Cardiovasc Transl Res; 2014 Dec; 7(9):769-80. PubMed ID: 25354998
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy.
Tompkins BA; Rieger AC; Florea V; Banerjee MN; Natsumeda M; Nigh ED; Landin AM; Rodriguez GM; Hatzistergos KE; Schulman IH; Hare JM
J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 30005555
[TBL] [Abstract][Full Text] [Related]
4. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
Hare JM; Fishman JE; Gerstenblith G; DiFede Velazquez DL; Zambrano JP; Suncion VY; Tracy M; Ghersin E; Johnston PV; Brinker JA; Breton E; Davis-Sproul J; Schulman IH; Byrnes J; Mendizabal AM; Lowery MH; Rouy D; Altman P; Wong Po Foo C; Ruiz P; Amador A; Da Silva J; McNiece IK; Heldman AW; George R; Lardo A
JAMA; 2012 Dec; 308(22):2369-79. PubMed ID: 23117550
[TBL] [Abstract][Full Text] [Related]
5. The impact of patient sex on the response to intramyocardial mesenchymal stem cell administration in patients with non-ischaemic dilated cardiomyopathy.
Florea V; Rieger AC; Natsumeda M; Tompkins BA; Banerjee MN; Schulman IH; Premer C; Khan A; Valasaki K; Heidecker B; Mantero A; Balkan W; Mitrani RD; Hare JM
Cardiovasc Res; 2020 Nov; 116(13):2131-2141. PubMed ID: 32053144
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty.
Golpanian S; DiFede DL; Pujol MV; Lowery MH; Levis-Dusseau S; Goldstein BJ; Schulman IH; Longsomboon B; Wolf A; Khan A; Heldman AW; Goldschmidt-Clermont PJ; Hare JM
Oncotarget; 2016 Mar; 7(11):11899-912. PubMed ID: 26933813
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Transendocardial Stem Cell Injection on Erectile Function in Men With Cardiomyopathy: Results From the TRIDENT, POSEIDON, and TAC-HFT Trials.
Ory J; Saltzman RG; Blachman-Braun R; Dadoun S; DiFede DL; Premer C; Hurwitz B; Hare JM; Ramasamy R
J Sex Med; 2020 Apr; 17(4):695-701. PubMed ID: 32059936
[TBL] [Abstract][Full Text] [Related]
8. [A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy].
Wang JA; Xie XJ; He H; Sun Y; Jiang J; Luo RH; Fan YQ; Dong L
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Feb; 34(2):107-10. PubMed ID: 16626573
[TBL] [Abstract][Full Text] [Related]
9. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.
Heldman AW; DiFede DL; Fishman JE; Zambrano JP; Trachtenberg BH; Karantalis V; Mushtaq M; Williams AR; Suncion VY; McNiece IK; Ghersin E; Soto V; Lopera G; Miki R; Willens H; Hendel R; Mitrani R; Pattany P; Feigenbaum G; Oskouei B; Byrnes J; Lowery MH; Sierra J; Pujol MV; Delgado C; Gonzalez PJ; Rodriguez JE; Bagno LL; Rouy D; Altman P; Foo CW; da Silva J; Anderson E; Schwarz R; Mendizabal A; Hare JM
JAMA; 2014 Jan; 311(1):62-73. PubMed ID: 24247587
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Tompkins BA; DiFede DL; Khan A; Landin AM; Schulman IH; Pujol MV; Heldman AW; Miki R; Goldschmidt-Clermont PJ; Goldstein BJ; Mushtaq M; Levis-Dusseau S; Byrnes JJ; Lowery M; Natsumeda M; Delgado C; Saltzman R; Vidro-Casiano M; Da Fonseca M; Golpanian S; Premer C; Medina A; Valasaki K; Florea V; Anderson E; El-Khorazaty J; Mendizabal A; Green G; Oliva AA; Hare JM
J Gerontol A Biol Sci Med Sci; 2017 Oct; 72(11):1513-1522. PubMed ID: 28977399
[TBL] [Abstract][Full Text] [Related]
11. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy.
Vrtovec B; Poglajen G; Lezaic L; Sever M; Socan A; Domanovic D; Cernelc P; Torre-Amione G; Haddad F; Wu JC
Circulation; 2013 Sep; 128(11 Suppl 1):S42-9. PubMed ID: 24030420
[TBL] [Abstract][Full Text] [Related]
12. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study).
Florea V; Rieger AC; DiFede DL; El-Khorazaty J; Natsumeda M; Banerjee MN; Tompkins BA; Khan A; Schulman IH; Landin AM; Mushtaq M; Golpanian S; Lowery MH; Byrnes JJ; Hendel RC; Cohen MG; Valasaki K; Pujol MV; Ghersin E; Miki R; Delgado C; Abuzeid F; Vidro-Casiano M; Saltzman RG; DaFonseca D; Caceres LV; Ramdas KN; Mendizabal A; Heldman AW; Mitrani RD; Hare JM
Circ Res; 2017 Nov; 121(11):1279-1290. PubMed ID: 28923793
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.
Hare JM; Traverse JH; Henry TD; Dib N; Strumpf RK; Schulman SP; Gerstenblith G; DeMaria AN; Denktas AE; Gammon RS; Hermiller JB; Reisman MA; Schaer GL; Sherman W
J Am Coll Cardiol; 2009 Dec; 54(24):2277-86. PubMed ID: 19958962
[TBL] [Abstract][Full Text] [Related]
14. Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients.
Golpanian S; El-Khorazaty J; Mendizabal A; DiFede DL; Suncion VY; Karantalis V; Fishman JE; Ghersin E; Balkan W; Hare JM
J Am Coll Cardiol; 2015 Jan; 65(2):125-32. PubMed ID: 25593053
[TBL] [Abstract][Full Text] [Related]
15. Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial.
Butler J; Epstein SE; Greene SJ; Quyyumi AA; Sikora S; Kim RJ; Anderson AS; Wilcox JE; Tankovich NI; Lipinski MJ; Ko YA; Margulies KB; Cole RT; Skopicki HA; Gheorghiade M
Circ Res; 2017 Jan; 120(2):332-340. PubMed ID: 27856497
[TBL] [Abstract][Full Text] [Related]
16. [Effects of intracoronary autologous bone marrow mononuclear cells transplantation in patients with dilated cardiomyopathy].
CHEN Y; GAO EM; GAO CY; XU Y; HUANG KJ; NIU ZM; ZHU ZY; YANG HH; LI MW
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Dec; 36(12):1087-91. PubMed ID: 19134276
[TBL] [Abstract][Full Text] [Related]
17. Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial.
Bolli R; Hare JM; Henry TD; Lenneman CG; March KL; Miller K; Pepine CJ; Perin EC; Traverse JH; Willerson JT; Yang PC; Gee AP; Lima JA; Moyé L; Vojvodic RW; Sayre SL; Bettencourt J; Cohen M; Ebert RF; Simari RD;
Am Heart J; 2018 Jul; 201():54-62. PubMed ID: 29910056
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Autologous Stem Cell-Patch Implantation for Patients With Heart Failure With Nonischemic Dilated Cardiomyopathy.
Domae K; Miyagawa S; Yoshikawa Y; Fukushima S; Hata H; Saito S; Kainuma S; Kashiyama N; Iseoka H; Ito E; Harada A; Takeda M; Sakata Y; Toda K; Pak K; Yamada T; Sawa Y
J Am Heart Assoc; 2021 Jul; 10(13):e008649. PubMed ID: 34212772
[TBL] [Abstract][Full Text] [Related]
19. A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration.
Natsumeda M; Florea V; Rieger AC; Tompkins BA; Banerjee MN; Golpanian S; Fritsch J; Landin AM; Kashikar ND; Karantalis V; Loescher VY; Hatzistergos KE; Bagno L; Sanina C; Mushtaq M; Rodriguez J; Rosado M; Wolf A; Collon K; Vincent L; Kanelidis AJ; Schulman IH; Mitrani R; Heldman AW; Balkan W; Hare JM
J Am Coll Cardiol; 2017 Nov; 70(20):2504-2515. PubMed ID: 29145950
[TBL] [Abstract][Full Text] [Related]
20. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up.
Vrtovec B; Poglajen G; Lezaic L; Sever M; Domanovic D; Cernelc P; Socan A; Schrepfer S; Torre-Amione G; Haddad F; Wu JC
Circ Res; 2013 Jan; 112(1):165-73. PubMed ID: 23065358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
